Adicet Bio (ACET) Free Cash Flow (2017 - 2026)
Adicet Bio (ACET) posted quarterly Free Cash Flow of -$21.5 million for Q1 2026, up 14.9% year-over-year from -$18.7 million in Q1 2025, and down 3.0% quarter-over-quarter from -$20.9 million in Q4 2025.
Adicet Bio (ACET) Free Cash Flow (2017 - 2026) Analysis & Trends
Adicet Bio's Free Cash Flow history runs 10 years deep, the most recent figure standing at -$21.5 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 14.9% year-over-year to -$21.5 million; the TTM figure through Mar 2026 stood at -$93.2 million (up 1.43% YoY), while the FY2025 annual figure was -$97.0 million, down 5.39% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$21.5 million, down from -$20.9 million in the prior quarter.
- The five-year high for Free Cash Flow was $1.5 million in Q1 2022, with the low at -$27.1 million in Q2 2025.
- The 5-year median for Free Cash Flow is -$23.6 million (2023), against an average of -$20.7 million.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow jumped 109.32% in 2022, then sank 1865.72% in 2023.
- Adicet Bio's Free Cash Flow stood at -$18.8 million in 2022, then retreated by 25.38% to -$23.6 million in 2023, then fell by 1.71% to -$24.0 million in 2024, then climbed by 13.01% to -$20.9 million in 2025, then declined by 3.0% to -$21.5 million in 2026.
- Business Quant data shows ACET's Free Cash Flow at -$21.5 million in Q1 2026, -$20.9 million in Q4 2025, and -$23.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Adicet Bio | 98.21 Mn | -19.98 Mn | - | -19.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.90 Mn |
| Jun 30, 2026 | -19.90 Mn |
| Mar 31, 2026 | -21.53 Mn |
| Mar 31, 2026 | -21.53 Mn |
| Dec 31, 2025 | -20.90 Mn |
| Dec 31, 2025 | -20.90 Mn |
| Sep 30, 2025 | -23.68 Mn |
| Sep 30, 2025 | -23.68 Mn |
| Jun 30, 2025 | -27.11 Mn |
| Jun 30, 2025 | -27.11 Mn |
| Mar 31, 2025 | -25.30 Mn |
| Mar 31, 2025 | -25.30 Mn |
| Dec 31, 2024 | -24.03 Mn |
| Dec 31, 2024 | -24.03 Mn |
| Sep 30, 2024 | -21.19 Mn |
| Sep 30, 2024 | -21.19 Mn |
| Jun 30, 2024 | -24.06 Mn |
| Jun 30, 2024 | -24.06 Mn |
| Mar 31, 2024 | -22.76 Mn |
| Mar 31, 2024 | -22.76 Mn |